https://031211.iqanda-cme.com/ 2024-11-16T01:43:30+0000 weekly 1 https://031211.iqanda-cme.com/iqanda-congenital-adrenal-hyperplasia-cah-medical-intelligence-zone 2024-12-17T18:57:21+0000 weekly 0.8 https://031211.iqanda-cme.com/resources-and-trials-in-congenital-adrenal-hyperplasia 2025-02-28T19:46:17+0000 weekly 0.8 https://031211.iqanda-cme.com/about-congenital-adrenal-hyperplasia-cah-medical-intelligence-zone 2026-02-28T01:43:18+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-are-the-current-dosages-for-glucocorticoid-therapy-and-what-markers-are-currently-followed-to-assess-adequacy-of-therapy-and-why-do-clinicians-have-an-incentive-to-lower-glucocorticoid-dose-in-persons-with-cah 2024-12-04T18:58:22+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-are-the-clinical-translational-implications-of-the-results-reported-thus-far-from-the-cahtalyst-trial-and-how-might-you-identify-patients-in-which-crinecerfont-would-address-unmet-therapeutic-need 2024-12-04T18:59:22+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-are-the-challenges-of-optimizing-therapy-even-with-glucocorticoids-considering-that-in-cah-the-aldosterone-androgen-and-glucocorticoid-pathways-are-coupled-with-one-another 2024-12-04T19:01:20+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-did-the-investigators-of-the-cahtalyst-pediatric-trial-observe-in-the-way-of-weight-loss-in-children-and-adolescents-was-this-a-pre-specified-secondary-end-point 2024-12-04T18:51:26+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/knowing-the-genetic-underpinnings-of-the-disease-how-does-this-impact-our-current-approach-to-cah-and-suggest-novel-approaches-for-targeting-specific-pathways-that-drive-the-hypothalamic-pituitary-axis-in-cah 2024-12-04T19:04:38+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/although-the-cahtalyst-trials-establish-that-you-can-improve-17-hydroxprogesterone-and-androstenedione-levels-while-lowering-the-glucocorticoid-dose-can-we-predict-long-term-benefits 2024-12-04T19:05:15+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/although-it-s-understood-that-there-are-a-panoply-of-glucocorticoid-related-side-effects-in-adults-with-cah-what-are-the-most-serious-and-prevalent-morbidities-that-you-ve-had-to-manage-in-your-practice 2024-12-04T18:48:30+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-do-you-think-are-the-most-important-clinical-implications-and-learnings-from-the-adult-and-pediatric-cahtalyst-trials 2024-12-04T18:51:48+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-be-kind-enough-to-give-us-some-background-regarding-your-research-and-clinical-experience-identifying-and-managing-pediatric-and-adult-patients-with-cah 2024-12-04T18:45:57+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/how-do-we-identify-patients-in-late-adolescence-who-might-benefit-from-reductions-in-steroid-dose-and-who-might-be-ideal-candidates-for-crf-antagonists-such-as-crinecerfont 2024-12-04T19:05:02+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-hormones-are-being/should-be-monitored-in-persons-with-cah-to-ensure-that-adequate-suppression-of-the-hpa-axis-has-been-achieved-that-is-clinically-meaningful 2024-12-04T19:01:31+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/based-on-the-mechanism-of-action-of-crinecerfont-and-the-results-of-the-pediatric-cahtalyst-trial-what-role-might-this-option-provide-for-pediatric-patients-with-cah 2024-12-04T18:59:34+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/once-the-diagnosis-of-21-oh-deficiency-cah-has-been-established-what-are-the-current-therapeutic-approaches-at-different-times-of-life-and-by-extension-what-are-the-unmet-therapeutic-needs 2024-12-04T19:06:55+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-discuss-the-specifics-of-the-adult-cahtalyst-trial-evaluating-crinecerfont-and-in-what-ways-it-was-similar-and-in-what-ways-did-elements-differ-from-the-pediatric-age-group 2024-12-04T18:52:01+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/does-the-pediatric-endocrinologist-have-reasons-to-be-concerned-about-toxicities-side-effects-and/or-complications-associated-with-long-term-corticosteroid-use-in-the-pediatric-patient-with-cah 2024-12-04T18:58:34+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-drill-down-into-the-findings-related-to-improved-insulin-sensitivity-and-reduced-bmi-reported-in-persons-with-cah-who-were-treated-with-crinecerfont 2026-03-02T21:21:04+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-should-we-look-to-in-the-future-as-far-as-our-improved-understanding-of-where-and-how-crf-antagonists-will-fit-into-the-therapeutic-landscape-for-cah 2024-12-04T19:04:51+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-discuss-the-complications-of-excessive-glucocorticoid-exposure-in-children-adolescents-and-adults-and-the-impact-on-cardiac-and-metabolic-morbidities-what-is-the-rational-for-looking-for-alternatives-to-glucocorticoid-therapy-for 2024-12-04T19:01:42+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/how-would-you-summarize-the-take-home-lessons-and-translational-implications-of-the-cahtalyst-trials-evaluating-crinecerfont-for-cah-in-adults-and-children 2024-12-04T18:52:13+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/how-do-the-clinical-end-points-and-therapeutic-concerns-change-as-persons-with-cah-become-adolescents-and-mature-into-early-adulthood 2024-12-04T19:06:42+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/based-on-your-experience-following-persons-with-cah-from-their-pediatric-years-into-adulthood-can-you-characterize-the-disease-burden-of-cah 2024-12-04T18:46:11+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-percentage-of-the-overall-participants-in-cahtalyst-demonstrated-improvement-in-either-the-glucocorticoid-dosing-or-the-androstenedione-lowering-end-point 2026-03-02T21:22:17+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-share-with-us-how-you-became-interested-in-cah-and-what-personal-and-discipline-related-historical-features-have-fueled-your-interest-in-advancing-therapy-for-this-disease-state 2026-02-27T23:25:47+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-discuss-the-cahtalyst-pediatric-strategies-aimed-at-understanding-whether-a-de-coupling-of-the-androstenedione-and-glucocorticoid-pathways-might-be-a-solution-for-reducing-the-burden-of-glucocorticoid-therapy 2024-12-04T19:01:55+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/although-you-have-emphasized-the-current-role-of-corticosteroid-therapy-in-cah-are-there-other-adjunctive-treatments-that-also-play-a-role 2024-12-04T19:06:31+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/given-the-long-term-sequelae-of-supra-physiologic-dosing-of-glucocorticoids-for-cah-what-therapeutic-strategies-are-being-considered-to-uncouple-the-cortisol-and-androgen-pathways 2024-12-04T18:46:23+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/once-the-importance-of-uncoupling-the-androstenedione-and-glucocorticoid-axes-was-understood-what-targeting-strategies-were-employed-in-the-cahtalyst-trial-that-would-lead-to-novel-targeting-of-crf1-with-crinecerfont-for-cah 2024-12-04T18:50:21+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-discuss-what-monitoring-and-therapeutic-end-points-i-e-glucocorticoid-sparing-were-selected-and-why-for-the-cahtalyst-trial-and-what-were-the-trial-s-primary-objectives 2024-12-04T19:02:08+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/given-the-co-morbidities-associated-with-supra-physiologic-doses-of-corticosteroids-what-is-the-rationale-for-inhibiting-the-hypothalamic-pituitary-adrenal-axis-upstream-by-using-the-crf1-receptor-antagonist-crinecerfont 2024-12-04T18:58:45+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-explain-the-difference-between-crh-corticotropin-releasing-hormone-and-crf-corticotropin-releasing-factor-or-are-you-referring-to-the-same-hormonal-factor 2024-12-04T18:46:35+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-strategies-are-used-to-compensate-for-glucocorticoid-mediated-side-effects 2024-12-04T19:06:20+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/from-a-near-future-perspective-what-do-you-believe-are-the-most-promising-approaches-to-reducing-metabolic-cardiometabolic-and-related-morbidities-in-adults-with-cah 2024-12-04T18:48:47+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/in-phase-1-of-the-cahtalyst-pediatric-study-did-investigators-demonstrate-a-statistically-significant-decrease-in-serum-androstenedione-from-baseline-with-crinecerfont-at-week-4-over-baseline 2024-12-04T19:02:20+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/any-cah-therapy-should-demonstrate-therapeutic-effects-over-the-long-haul-can-you-summarize-which-end-points-glucocorticoid-dose-stability-and-lowering-androstenedione-reduction-bmi-and-others-were-maintained-over-the-long-term-with-crin 2026-03-02T21:22:49+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-briefly-summarize-how-you-developed-your-interest-in-cah 2024-12-04T19:00:42+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-drill-down-to-the-specific-parameters-inclusion-criteria-glucocorticoid-dosing-set-points-for-androstenedione-control-overall-2-part-trial-design-for-the-pediatric-cahtalyst-trial 2024-12-04T18:50:34+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-provide-an-overview-of-cah-how-the-diagnosis-is-made-with-newborn-screening-and-what-the-current-deficiencies-are-in-therapy 2024-12-21T22:08:32+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/for-this-iqanda-cah-medical-intelligence-zone-can-you-introduce-us-to-what-you-plan-to-discuss-in-particular-the-new-data-introduced-at-endo-in-which-more-definitive-long-term-follow-up-data-was-presented-for-the-cahtalyst-adult-and-pedi 2026-03-02T21:19:51+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/if-the-rationale-for-upstream-decoupling-of-the-androgen-and-cortisol-pathways-at-the-level-of-crf-inhibition-is-confirmed-what-are-the-potential-advantages-in-terms-of-reducing-glucocorticoid-dose 2024-12-04T18:46:47+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-tell-us-a-bit-about-the-history-of-cah-how-it-was-discovered-and-what-has-shaped-your-lifelong-interest-in-this-condition-especially-in-the-pediatric-population 2024-12-04T19:04:12+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-discuss-the-12-month-data-from-the-cahtalyst-trials-reporting-on-long-term-results-in-both-adult-and-pediatric-populations-with-cah-including-persons-who-were-started-on-crinecerfont-as-well-as-those-who-crossed-over-to-the-crine 2026-03-02T21:21:43+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-are-the-typical-glucocorticoid-replacement-doses-used-for-person-with-cah 2024-12-04T18:49:00+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-can-you-tell-us-about-some-of-the-key-features-of-the-cahtalyst-pediatric-trial-including-retention-of-trial-subjects-and-achieving-androstenedione-end-points-in-patients-on-crinecerfont 2024-12-04T19:02:36+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/since-you-ve-treated-adults-with-cah-who-have-been-on-glucocorticoids-for-many-years-what-are-the-long-term-side-effects-and-complications-that-have-required-management 2024-12-04T18:46:59+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/are-there-additional-data-readouts-we-can-expect-from-the-cahtalyst-trials-that-have-not-been-reported-yet 2026-03-02T21:23:23+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-discuss-the-problematic-aspects-of-long-term-corticosteroid-treatment-in-cah-including-the-challenges-of-delivering-the-right-supra-physiologic-doses-of-corticosteroid-treatment 2024-12-04T19:06:09+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/please-discuss-the-two-phases-of-the-cahtalyst-trial-in-which-you-compared-the-placebo-group-with-the-crinecerfont-arm-and-the-ability-to-maintain-a-down-titrated-more-physiological-glucocorticoid-dose 2024-12-04T18:50:48+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-are-the-unique-elements-of-the-trial-design-for-the-cahtalyst-trial-which-evaluated-crinecerfont-in-children-and-adolescents-for-the-treatment-of-congenital-adrenal-hyperplasia 2024-12-04T18:58:57+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-strategies-are-being-explored-to-permit-the-lowest-possible-dose-of-glucocorticoids-to-mitigate-the-metabolic-disease-burden-associated-with-chronic-administration-in-cah 2024-12-04T18:48:02+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/in-the-second-phase-of-the-cahtalyst-pediatric-trial-can-you-discuss-initiating-down-titration-of-glucocorticoid-therapy-and-what-levels-of-glucocorticoid-sparing-were-targeted 2024-12-04T19:02:50+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-novel-strategies-in-particular-crf-receptor-antagonism-with-crinecerfont-might-be-considered-address-the-therapeutic-burden-associated-with-glucocorticoid-therapy-in-cah 2024-12-04T19:05:57+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-does-the-landscape-look-like-for-diagnosing-assessing-and-monitoring-persons-adult-and-pediatric-who-are-suspected-of-having-or-have-confirmed-cah 2024-12-04T19:00:55+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/based-on-the-cahtalyst-pediatric-trial-were-you-able-to-down-titrate-glucocorticoid-doses-in-phase-2-evaluating-the-potential-of-crinecerfont-to-achieve-glucocorticoid-sparing-in-persons-with-cah 2024-12-04T19:03:02+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-go-into-the-specific-end-points-for-androstenedione-as-well-as-your-criteria-for-allowing-progressive-down-titration-of-glucocorticoid-in-phase-2-of-the-cahtalyst-trial 2024-12-04T18:51:00+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/based-on-the-phase-3-trial-of-crinecerfont-in-pediatric-cah-the-cahtalyst-trial-which-patients-are-most-likely-suitable-candidates-for-treatment-with-this-novel-therapey 2024-12-04T19:05:46+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-is-the-current-mainstay-of-treatment-for-cah-what-are-the-short-and-long-term-complications-of-present-approaches-based-on-corticosteroid-therapy-that-encourage-development-of-alternative-therapies 2024-12-04T18:58:09+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/based-on-the-cahtalyst-pediatric-trial-what-subgroups-of-children-and-adults-with-classical-cah-represent-ideal-patients-for-treatment-with-crf1-targeting-inhibitors-such-as-crinecerfont 2024-12-04T19:03:16+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-were-you-trying-to-learn-in-the-second-phase-of-cahtalyst-whether-or-not-you-needed-super-physiologic-doses-of-glucocorticoids-to-reduce/maintain-androstenedione-in-combination-with-upstream-crf1-inhibition-mediated-by-crinecerfont 2024-12-04T18:51:13+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-were-the-findings-from-the-cahtalyst-trial-in-terms-of-the-ability-of-the-crf1-receptor-antagonist-crinecerfont-to-reduce-hydrocortisone-dose-while-maintaining-acceptable-androstenedione-levels 2024-12-04T18:59:09+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-discuss-the-genetics-of-cah-specifically-how-specific-alterations-affect-clinical-presentation-the-pathophysiology-of-cah-and-its-therapeutic-implications 2024-12-04T19:04:24+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-provide-a-summary-of-the-pathobiology-and-hormonal-ramifications-of-the-classic-form-of-cah-caused-by-21-oh-deficiency-and-the-unmet-need-for-therapies-that-address-hormonal-derangments 2024-12-04T19:01:07+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/can-you-discuss-the-purpose-of-establishing-the-cahtalog-registry-and-how-the-insights-gleaned-from-this-database-help-us-better-understand-the-burden-of-cah-and-how-it-highlights-the-unmet-need-for-better-therapies-for-cah 2026-03-02T21:20:34+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/given-the-consensus-that-glucocorticoid-dose-reduction-is-imperative-for-reducing-long-term-disease-burden-and-adverse-metabolic-effects-what-degree-of-reduction-should-be-considered-in-persons-with-cah 2024-12-04T18:48:16+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/what-glucocorticoid-dosing-and/or-biomarker-metrics-such-as-17-hydroxyprogesterone-might-you-consider-when-assessing-suitability-for-crf-receptor-antagonism-with-crinecerfont-in-the-setting-of-cah 2024-12-04T19:05:28+0000 weekly 0.8 https://031211.iqanda-cme.com/videos/how-well-was-crinecerfont-tolerated-in-the-cahtalyst-pediatric-trial-and-what-was-the-side-effect-profile 2024-12-04T18:51:37+0000 weekly 0.8 https://031211.iqanda-cme.com/courses/iqanda-congenital-adrenal-hyperplasia-cah-medical-intelligence-zone 2026-02-28T01:44:29+0000 weekly 0.8